Ampio enrolls patients in COVID-19 clinical trial

By The Science Advisory Board staff writers

July 23, 2020 -- Ampio Pharmaceuticals has begun patient enrollment for its previously announced COVID-19 phase I clinical trial to evaluate its Ampion drug candidate.

Ampion is based on an immunomodulatory molecule derived from the N-terminus of the human serum albumin. The trial will evaluate its intravenous application as a treatment for patients with COVID-19 who are on supplemental oxygen.

Ampio begins COVID-19 phase I clinical trial for immunotherapy
Ampio Pharmaceuticals will begin a phase I clinical trial to evaluate its Ampion drug candidate for treatment of COVID-19 patients who are on supplemental...
Immunic begins phase II immunotherapy for COVID-19
Immunic has enrolled the first COVID-19 patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase (DHODH) inhibitor.

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter